GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » ROC (Joel Greenblatt) %

Ocumension Therapeutics (HKSE:01477) ROC (Joel Greenblatt) % : -74.69% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Ocumension Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -74.69%.

The historical rank and industry rank for Ocumension Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:01477' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -77298.74   Med: -2757.15   Max: -81.75
Current: -82.76

During the past 6 years, Ocumension Therapeutics's highest ROC (Joel Greenblatt) % was -81.75%. The lowest was -77298.74%. And the median was -2757.15%.

HKSE:01477's ROC (Joel Greenblatt) % is ranked better than
68.68% of 1459 companies
in the Biotechnology industry
Industry Median: -330.28 vs HKSE:01477: -82.76

Ocumension Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 76.10% per year.


Ocumension Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Ocumension Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics ROC (Joel Greenblatt) % Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -77,298.74 -5,397.78 -116.52 -94.31 -81.75

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -144.12 -93.54 -92.36 -91.96 -74.69

Competitive Comparison of Ocumension Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Ocumension Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's ROC (Joel Greenblatt) % falls into.



Ocumension Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(95.765 + 31.623 + 30.241) - (206.762 + 0 + 12.706)
=-61.839

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(121.367 + 35.518 + 4.704) - (98.178 + 0 + 101.938)
=-38.527

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Ocumension Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-373.046/( ( (487.447 + max(-61.839, 0)) + (511.507 + max(-38.527, 0)) )/ 2 )
=-373.046/( ( 487.447 + 511.507 )/ 2 )
=-373.046/499.477
=-74.69 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics  (HKSE:01477) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Ocumension Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (HKSE:01477) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Executives
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Liu Ye 2101 Beneficial owner
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Chen Ziqing 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Boyu Capital Fund Iv, L.p 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd 2201 Interest of corporation controlled by you
Summer Iris Limited 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines